Please try another search
For the nine months ended 30 September 2015, Ocata Therapeutics Inc revenues increased 38% to $163K. Net loss applicable to common stockholders decreased 35% to $18.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Loss on settlement of litigation decrease from $11.6M (expense) to $0K, Adjustments to Fair Value of Derivatives increase from $719K to $3.9M (income).
Period Ending: | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 |
---|---|---|---|---|
Total Revenue | 0.08 | 0.04 | 0.04 | 0.04 |
Gross Profit | 0.07 | 0.02 | 0.02 | 0.02 |
Operating Income | -7.41 | -6.68 | -7.04 | -6.84 |
Net Income | -3.85 | -7.25 | -7.04 | -6.82 |
Period Ending: | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 |
---|---|---|---|---|
Total Assets | 33.47 | 33.34 | 4.88 | 5.74 |
Total Liabilities | 19.71 | 17.15 | 6.96 | 8.47 |
Total Equity | 13.76 | 16.19 | -2.09 | -2.74 |
Period Ending: | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -19.26 | -13.69 | -6.99 | -21.45 |
Cash From Investing Activities | -0.13 | -0.12 | -0.02 | -0.26 |
Cash From Financing Activities | 47.1 | 41.24 | 6.12 | 24.39 |
Net Change in Cash | 27.71 | 27.43 | -0.89 | 2.68 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review